ATE480532T1 - Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon - Google Patents

Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon

Info

Publication number
ATE480532T1
ATE480532T1 AT07733504T AT07733504T ATE480532T1 AT E480532 T1 ATE480532 T1 AT E480532T1 AT 07733504 T AT07733504 T AT 07733504T AT 07733504 T AT07733504 T AT 07733504T AT E480532 T1 ATE480532 T1 AT E480532T1
Authority
AT
Austria
Prior art keywords
short
term action
salts
polymorphous forms
benzodiazepine
Prior art date
Application number
AT07733504T
Other languages
English (en)
Inventor
Gary Tilbrook
Louisa Quegan
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613692A external-priority patent/GB0613692D0/en
Priority claimed from GB0613694A external-priority patent/GB0613694D0/en
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Application granted granted Critical
Publication of ATE480532T1 publication Critical patent/ATE480532T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Steroid Compounds (AREA)
AT07733504T 2006-07-10 2007-07-10 Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon ATE480532T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0613692A GB0613692D0 (en) 2006-07-10 2006-07-10 Benzodiazepine salts
GB0613694A GB0613694D0 (en) 2006-07-10 2006-07-10 Benzodiazepine salts
PCT/GB2007/002565 WO2008007071A1 (en) 2006-07-10 2007-07-10 Short-acting benzodiazepine salts and their polymorphic forms

Publications (1)

Publication Number Publication Date
ATE480532T1 true ATE480532T1 (de) 2010-09-15

Family

ID=38535381

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07733504T ATE480532T1 (de) 2006-07-10 2007-07-10 Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon

Country Status (18)

Country Link
US (6) US9193730B2 (de)
EP (1) EP2081921B1 (de)
JP (2) JP5433413B2 (de)
KR (3) KR20150081370A (de)
CN (3) CN103288834B (de)
AT (1) ATE480532T1 (de)
AU (1) AU2007274054B2 (de)
BR (1) BRPI0714886B8 (de)
CA (1) CA2657347C (de)
DE (1) DE602007009128D1 (de)
DK (1) DK2081921T3 (de)
HK (4) HK1137739A1 (de)
MX (1) MX2009000404A (de)
PL (1) PL2081921T3 (de)
PT (1) PT2081921E (de)
RU (1) RU2470935C2 (de)
SI (1) SI2081921T1 (de)
WO (1) WO2008007071A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
KR20150081370A (ko) 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EP2305647A1 (de) * 2009-09-18 2011-04-06 PAION UK Limited Verfahren zur Herstellung von 3-[(4S)-8-brom-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propionsäuremethylester oder das Benzensulfonatsalz davon und in diesem Prozess nützliche Verbindungen
EP2450039A1 (de) 2010-11-08 2012-05-09 PAION UK Ltd. Dosierschema zur Sedierung mit CNS 7056 (Remimazolam)
MA37581B1 (fr) * 2012-05-22 2016-07-29 Paion Uk Ltd Compositions comprenant des benzodiazépines à action rapide
SG11201501358SA (en) * 2012-08-31 2015-04-29 Paion Uk Ltd Method for administering hypnotic/sedative agent
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106804107B (zh) * 2014-07-23 2019-03-12 江苏恩华络康药物研发有限公司 新的苯并二氮杂*类衍生物及其用途
US20170081954A1 (en) * 2015-09-23 2017-03-23 Tesco Corporation Pipe joint location detection system and method
CN107266452A (zh) * 2016-04-08 2017-10-20 四川科伦药物研究院有限公司 苯并二氮杂*衍生物的盐及其晶体形式、制备方法和用途
CN109641000A (zh) 2016-04-14 2019-04-16 Paion英国有限公司 经口吸入和经鼻用的苯并二氮杂*类
CN108503644B (zh) * 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
PT3580219T (pt) 2017-02-09 2022-06-02 Assia Chem Ind Ltd Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam
CN108948018B (zh) * 2017-05-17 2021-03-30 四川科伦博泰生物医药股份有限公司 苯并二氮*衍生物及其盐和相关晶体形式、制备方法和用途
AU2019222052B2 (en) 2018-02-13 2022-05-12 Jiangsu Nhwaluokang Pharmaceutical Research And Development Co., Ltd. Benzodiazepine derivative hydrochloride and crystal form, preparation method, and application thereof
CN110398514B (zh) * 2018-04-24 2023-04-28 恒天纤维集团有限公司 一种快速判断纤维素胶液中金属杂质含量的方法
ES2803099B2 (es) 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
WO2023037237A1 (en) * 2021-09-09 2023-03-16 Wavelength Enterprises Ltd Process for the preparation of remimazolam
WO2023194945A1 (en) 2022-04-08 2023-10-12 Fresenius Kabi Oncology Ltd. An improved process for the preparation of remimazolam
CN115448927A (zh) * 2022-10-20 2022-12-09 重庆瑞泊莱医药科技有限公司 一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
BR6915069D0 (pt) 1969-02-28 1973-08-16 Upjohn Co Compostos organicos e processo
GB1329464A (en) 1969-09-01 1973-09-12 Takeda Chemical Industries Ltd Process for producing benzodiazepine derivatives
DE2156472A1 (de) 1970-11-23 1972-05-31 Ciba-Geigy Ag, Basel (Schweiz) Verfahren zur Herstellung von neuen Diazepinderivaten
US3933794A (en) * 1971-08-04 1976-01-20 The Upjohn Company 2-(2-Alkynylamino)-3H-1,4-benzodiazepines
FR2183716A1 (en) 1972-05-05 1973-12-21 Centre Etd Ind Pharma Substd-6-phenyl-4h-imidazo (1,2-a)-1,4-benzo diazepines - - tranquillisers anxiolytics,sedatives and muscle-relaxants
IE41197B1 (en) 1973-05-29 1979-11-07 Squibb & Sons Inc 4h-s-triazolo (4,3-a)(1,5)benzodiazepin-5-ones
CH608234A5 (en) 1974-08-30 1978-12-29 Crc Ricerca Chim Process for the preparation of lithium salts of 1,4-benzodiazepines
DE2900017A1 (de) 1978-01-10 1979-07-12 Clin Midy 3-alkoxycarbonyl-benzodiazepin- derivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
MC1528A1 (fr) 1982-07-21 1984-04-13 Hoffmann La Roche Imidazobenzodiazepines
IT1165588B (it) 1983-03-23 1987-04-22 Medosan Ind Biochimi 1,4 benzodiazepine terapeuticamente attive
CA1332410C (en) 1984-06-26 1994-10-11 Roger M. Freidinger Benzodiazepine analogs
US4755508A (en) 1984-06-26 1988-07-05 Merck & Co., Inc. Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
US4820834A (en) 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
US4724237A (en) 1984-06-26 1988-02-09 Merck & Co., Inc. 2-substituted-aminomethyl-1,4-benzodiazepines
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
ATE132974T1 (de) 1986-10-24 1996-01-15 Abbott Lab Test, indikatoren, immunogene und antikörper für benzodiazepine
EP0368972B1 (de) 1988-04-29 1993-08-18 Baker Norton Pharmaceuticals, Inc. Verfahren zur sicheren anästhesie oder bewusstseinssedierung
US5019583A (en) * 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
DK0411668T4 (da) 1989-08-04 1999-08-09 Merck Sharp & Dohme Central-chlolecystokinin-antagonister til behandling af psykiske forstyrrelser
DE122009000062I2 (de) 1989-10-20 2011-01-13 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
IE904560A1 (en) 1989-12-18 1991-06-19 Merck & Co Inc New benzodiazepine analogs
IL96613A0 (en) 1989-12-18 1991-09-16 Merck & Co Inc Pharmaceutical compositions containing benzodiazepine analogs
US5220017A (en) 1991-04-10 1993-06-15 Merck & Co., Inc. Cholecystokinin antagonists
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
CA2071181A1 (en) 1991-06-14 1992-12-15 Roger M. Freidinger Benzodiazepine analogs
GB9117852D0 (en) 1991-08-19 1991-10-09 Merck Sharp & Dohme Therapeutic agents
WO1993007129A1 (en) 1991-10-11 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Remedy for osteoporosis and diazepine compound
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
CA2143246C (en) * 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
US5834464A (en) * 1994-11-18 1998-11-10 Merck & Co., Inc. Imidazolinobenzodiazepines
ATE203026T1 (de) 1995-01-06 2001-07-15 Hoffmann La Roche Hydroxymethyl-imidazodiazepine und deren ester
WO1996023790A1 (de) 1995-02-02 1996-08-08 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepine
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
EP0907644A4 (de) 1996-06-28 2003-02-05 Merck & Co Inc Pharmazeutische zubereitung
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP0881235A1 (de) 1997-05-26 1998-12-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Phosphor Ylide, Herstellung und Verwendung zu schwachnukleophilen starkbasischen Verbindungen
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
EP1161949A1 (de) 2000-06-09 2001-12-12 Warner-Lambert Company Verwendung von diazepinoindolen zur behandlung von chronisch obstruktiver lungenkrankheiten
KR100717098B1 (ko) 2002-02-28 2007-05-10 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
EP2422806A3 (de) 2004-02-11 2012-06-13 Amylin Pharmaceuticals Inc. Hybridpolypeptide mit auswahlbaren Eigenschaften
US7687736B2 (en) 2004-04-29 2010-03-30 Smart Technologies Ulc Tensioned touch panel and method of making same
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
US8039460B2 (en) 2004-10-13 2011-10-18 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7632832B2 (en) 2005-01-18 2009-12-15 Merck & Co., Inc. CGRP receptor antagonists
WO2006088894A2 (en) 2005-02-15 2006-08-24 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20070040501A1 (en) 2005-08-18 2007-02-22 Aitken Bruce G Method for inhibiting oxygen and moisture degradation of a device and the resulting device
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
GB0613692D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
KR20150081370A (ko) * 2006-07-10 2015-07-13 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
ES2600477T3 (es) 2007-05-22 2017-02-09 Chemocentryx, Inc. 3-(Imidazolil)-pirazolo[3,4-b]piridinas
WO2009145323A1 (ja) 2008-05-30 2009-12-03 日産化学工業株式会社 多環式化合物を用いるアルコールの酸化方法
JP2012505843A (ja) 2008-10-16 2012-03-08 パイオン ユーケー リミテッド 術後疼痛管理のための極性オピオイドの投与スキーム
JP4669584B2 (ja) 2009-03-30 2011-04-13 日本製紙株式会社 Ｎ−オキシル化合物の回収・再利用方法
EP2305647A1 (de) 2009-09-18 2011-04-06 PAION UK Limited Verfahren zur Herstellung von 3-[(4S)-8-brom-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propionsäuremethylester oder das Benzensulfonatsalz davon und in diesem Prozess nützliche Verbindungen
ES2564318T3 (es) 2009-11-05 2016-03-21 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina
JP5635275B2 (ja) 2010-01-28 2014-12-03 日清紡ホールディングス株式会社 アルコールの酸化方法
EP2450039A1 (de) 2010-11-08 2012-05-09 PAION UK Ltd. Dosierschema zur Sedierung mit CNS 7056 (Remimazolam)
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途
JP5585597B2 (ja) 2012-01-27 2014-09-10 株式会社デンソー 車輪位置検出装置およびそれを備えたタイヤ空気圧検出装置
MA37581B1 (fr) 2012-05-22 2016-07-29 Paion Uk Ltd Compositions comprenant des benzodiazépines à action rapide
SG11201501358SA (en) 2012-08-31 2015-04-29 Paion Uk Ltd Method for administering hypnotic/sedative agent
WO2014047903A1 (zh) 2012-09-28 2014-04-03 华为技术有限公司 信道状态信息进程处理方法、网络设备和用户设备
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión

Also Published As

Publication number Publication date
RU2470935C2 (ru) 2012-12-27
CN103288834A (zh) 2013-09-11
US9914738B2 (en) 2018-03-13
US20180186803A1 (en) 2018-07-05
MX2009000404A (es) 2009-06-26
CN104059072B (zh) 2016-06-22
JP5785923B2 (ja) 2015-09-30
KR20150081370A (ko) 2015-07-13
US9193730B2 (en) 2015-11-24
AU2007274054B2 (en) 2012-05-24
KR20170091770A (ko) 2017-08-09
CA2657347C (en) 2014-11-18
JP2013049690A (ja) 2013-03-14
HK1202113A1 (zh) 2015-09-18
BRPI0714886B8 (pt) 2021-05-25
AU2007274054A1 (en) 2008-01-17
US10961250B2 (en) 2021-03-30
HK1137739A1 (en) 2010-08-06
CN103288834B (zh) 2015-07-15
EP2081921A1 (de) 2009-07-29
WO2008007071A1 (en) 2008-01-17
PT2081921E (pt) 2010-12-10
JP5433413B2 (ja) 2014-03-05
RU2009104311A (ru) 2010-08-20
US20160176881A1 (en) 2016-06-23
CN104059072A (zh) 2014-09-24
HK1189383A1 (en) 2014-06-06
SI2081921T1 (sl) 2011-01-31
JP2009542785A (ja) 2009-12-03
US20180002338A1 (en) 2018-01-04
CA2657347A1 (en) 2008-01-17
HK1202114A1 (zh) 2015-09-18
US10472365B2 (en) 2019-11-12
KR20090045233A (ko) 2009-05-07
CN104059071A (zh) 2014-09-24
US20100081647A1 (en) 2010-04-01
DK2081921T3 (da) 2011-01-03
DE602007009128D1 (de) 2010-10-21
EP2081921B1 (de) 2010-09-08
CN104059071B (zh) 2016-06-22
US20210261556A1 (en) 2021-08-26
US20200039990A1 (en) 2020-02-06
PL2081921T3 (pl) 2011-03-31
BRPI0714886B1 (pt) 2021-04-13
BRPI0714886A2 (pt) 2013-03-26
US9777007B2 (en) 2017-10-03

Similar Documents

Publication Publication Date Title
ATE480532T1 (de) Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon
ATE461927T1 (de) Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon
ECSP11011181A (es) Compuestos orgánicos
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
ECSP109964A (es) Pirimidinas bicíclicas fusionadas
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
ATE553104T1 (de) Substituierte 1h-benzimidazol-4-carboxamide als potente parp-hemmer
ME01532B (me) Jedinjenja
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
CL2008001345A1 (es) Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras.
MX2009005358A (es) Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2.
EA201101186A1 (ru) Конденсированные пиримидины
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
EA200901034A1 (ru) 6-БЕНЗИЛ-2,3,4,7-ТЕТРАГИДРОИНДОЛО [2,3-c]ХИНОЛИНЫ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФДЭ5 (ФОСФОДИЭСТЕРАЗЫ 5)
EA201100303A1 (ru) Производные пиразоло[5,1-b]оксазола в качестве антагонистов cfr1
ATE512968T1 (de) 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung
EA201170563A1 (ru) Метиленамины тиено[2,3-d]пиримидина и их применение в качестве антагонистов рецепторов a2a аденозина
AR069867A1 (es) Sales maleat0, besilato y l-malato de 6-(5-cloro-2-piridil) -5- ((4-metil-1-piperazinil)carboniloxi) -7-oxo-6, 7- dihidro-5h-pirrolo (3,4-b) pirazina
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2081921

Country of ref document: EP